While we found large effect sizes of 1.11 and 1.19 for tumour infiltration of CD56+ cells and peripheral NK cell degranulation, respectively, we would recommend future trials to anticipate on a medium effect size of 0.50 or perhaps a large effect size of 0.80. The gene discussed is NCAM1; the disease is neoplasm.